Cost-Effectiveness Analysis of Favipiravir and Remdesivir as COVID-19 Treatment in South Tangerang, Banten Province - Indonesia
Abstract
COVID-19 is a contagious ailment primarily attributed to the severe acute respiratory syndrome coronavirus. Indonesia persists in confronting the COVID-19 pandemic, and South Tangerang City has emerged as one of the municipalities in Indonesia that has been significantly affected. There are two categories of medications employed for COVID-19 treatment according to government policies, namely favipiravir and remdesivir. This study aims to as- sess the cost-effectiveness of favipiravir and remdesivir medications at the South Tangerang General Hospital, Indonesia. The present study employs a retrospective research design characterized by a quantitative approach, utilizing cross-sectional methodologies. The analy- sis mostly consists of descriptive techniques. The sample consisted of 479 individuals, with 246 individuals receiving outpatient treatment and 233 undergoing inpatient treatment. The inclusion criteria for this study consisted of individuals diagnosed with COVID-19 who had tested positive for the antiviral medications favipiravir and remdesivir. The findings indicated that the Average Cost-Effectivenss Ratio (ACER) for inpatients treated with fa- vipiravir was IDR 2,354,319,859, but for those treated with remdesivir, it amounted to IDR 3,501,513,488. Regarding the outpatient population utilizing favipiravir, the total expendi- ture amounts to IDR 420,083,118. Similarly, patients utilizing remdesivir incur a total ex- penditure of IDR 797,282,432. It is worth noting that the Cost-Effectivenss Ratio (CER) for patients using favipiravir is IDR 1,545,621, whereas patients using remdesivir have a CER of IDR 2,309,705. This study makes a valuable contribution to the existing body of research by demonstrating the cost-effectiveness of favipiravir. Consequently, future studies inves- tigating the overall effectiveness of favipiravir in COVID-19 patients must employ more comprehensive criteria.
Keywords
Full Text:
PDFReferences
WHO, 2023. WHO Coronavirus (COVID-19) Dashboard. World Health Organization. URL https://www.who.int/publications (accessed 12.29.23).
Kabar Tangsel, 2023. Data Pantauan COVID-19 Kota Tangerang Selatan. Pemerintah Kota Tangerang Selatan. URL https://lawancovid19.tangerangselatankota.go.id/ (accessed 12.29.23).
Bartsch, S.M., Ferguson, M.C., McKinnell, J.A., O’Shea, K.J., Wedlock, P.T., Siegmund, S.S., Lee, B.Y., 2020. The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States. Health Aff 39, 927–935. https://doi.org/10.1377/hlthaff.2020.00426
Isnariani, T.A., Andarini, M., Lukino, P.K., 2022. Informatorium Obat Covid-19 Di Indonesia Edisi 4 Badan Pengawas Obat Dan Makanan Republik Indonesia, 4th ed. Badan Pengawas Obat dan Makanan, Jakarta.
Rahmandani Arif, Sarnianto Prih, Anggriani Yusi, & Purba Fredrick Dermawan. (2021). Analisis Efektivitas Biaya Penggunaan Obat Antivirus Oseltamivir dan Favipiravir pada Pasien COVID-19 Derajat Sedang di Rumah Sakit Sentra Medika Cisalak Depok. Majalah Farmasetika, 6(1), 133–144.
Sarvasti, D., 2020. Pengaruh Gender Dan Manifestasi Kardiovaskular Pada COVID-19. Indonesian Journal of Cardiology 41, 126–32. https://doi.org/10.30701/ijc.1004
Halimbar, A.N., Lorensia, A., Ramadani, D., 2023. Cost-Effectiveness Analysis Of Remdesivir And Favipiravir Therapy For The Treatment Of Covid-19 In Adult Patients At The Hajj Regional General Hospital, East Java Province. Jurnal Scientia 12, 348–354.
Fathurrahman, M.H., Simanjuntak, N., Sopiah, N.S., 2023. Analisis Efektivitas Biaya Penggunaan Obat Pada Pasien Rawat Inap Penyakit Covid-19 Kategori Suspek Non-Comorbid Dengan Terapi Obat Kombinasi Antivirus Dan Antibiotik Di Salah Satu Rumah Sakit Kota Bandung Periode Juli-Desember 2021. Jurnal Sains dan Ilmu Farmasi 8, 24–34.
Safarina, N.A., Amalia, I., Dewi, R., 2021. Analisis Beban Kerja Dan Stres Ibu Yang Bekerja Pada Masa Pandemi Covid- 19. Jurnal Diversita 7, 157–167. https://doi.org/10.31289/diversita.v7i2.4540
Khaerunnisa, R., Rumana, N. A., Yulia, N., & Fannya, P. (2022). Gambaran Karakteristik Pasien COVID-19 di Rumah Sakit Mekar Sari Bekasi Tahun 2020-2021. Jurnal Manajemen Informasi Kesehatan Indonesia, 10(1), 72.
Burhan, E., Dwi Susanto, A., Isbaniah, F., Aman Nasution, S., Ginanjar, E., Wicaksono Pitoyo, C., Susilo, A., Firdaus, I., Santoso, A., Arifa Juzar, D., Kamsul Arif, S., Lolong Wulung, N.G., Muchtar, F., Pulungan, A.B., Ambara Sjakti, H., Prawira, Y., Dwi Putri TIM PENYUSUN Erlina Burhan, N., Adityaningsih, D., Fahrial Syam, A., Rasmin, M., Rengganis, I., Sukrisman, L., Damayanti, T., Heru Wiyono, W., Elhidsi, M., Aniwidyaningsih, W., Handayani, D., Sugiri, J.R., Rizal Wahyudi, E., Ayu Mulansari, N., Juli Edi Tarigan, T., Hidayat, R., Martin Rumende, C., Yuwono Soeroto, A., Astha Triyono, E., Katu, S., Agustina, P., Puspitorini, D., Prasetya Wijaya, I., Musbah, T., Pudjiadi, A.H., Yanuarso, P.B., Alam, A., Kaswandani, N., Dwi Putri, N., Taufiq Kadafi, K., Roeslaini, R.D., Mayung Sambo, C., 2020. PEDOMAN TATALAKSANA COVID-19 Edisi 3 TIM EDITOR Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN) Ikatan Dokter Anak Indonesia (IDAI).
Liu, X., Liu, C., Liu, G., Luo, W., & Xia, N. (2020). COVID-19: Progress in diagnostics, therapy and vaccination. In Theranostics (Vol. 10, Issue 17, pp. 7821–7835). Ivyspring International Publisher.
Ghasemnejad-Berenji, M., & Pashapour, S. (2021). Favipiravir and COVID-19: A Simplified Summary. Drug Research. 71(3). 166–170.
Joshi, S., Parkar, J., Ansari, A., Vora, A., Talwar, D., Tiwaskar, M., Patil, S., & Barkate, H. (2021). Role of favipiravir in the treatment of COVID-19. In International Journal of Infectious Diseases (Vol. 102, pp. 501–508). Elsevier B.V.
Giusman, R., & Nurwahyuni, A. (2022). Biaya Pengobatan Pasien Rawat Inap COVID-19 di Rumah Sakit X Tahun 2021. Jurnal Ekonomi Kesehatan Indonesia, 7(2).
Setyarini, Y., Suryawati, C., Pawelas Arso, S., Kariadi Semarang, R., & Kesehatan Masyarakat, F. (2022). Analisis Pembiayaan COVID-19 di RSUP dr. Kariadi Semarang. Jurnal Manajemen Kesehatan Indonesia, 10(2), 191–201.
Alamer, A., Almutairi, A.R., Halloush, S., Al-jedai, A., Alrashed, A., AlFaifi, M., Mohzari, Y., Almutairi, M., AlHassar, F., Howaidi, J., Almutairi, W., Abraham, I., Alkhatib, N., 2023. Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals. Saudi Pharmaceutical Journal 31, 510–516. https://doi.org/10.1016/j.jsps.2023.02.003.
Ramadani, D., Lorensia, A., & Nugraha, A. (2023). Cost-Effectiveness Analysis of Remdesivir and Favipiravir Therapy for The Treatment of Covid-19 In Adult Patients at DR. Soetomo General Hospital, East Java Province. Jurnal Administrasi Kesehatan Indonesia, 11(01), 102–112.
Setiadi, F., Nur, W.M., Indonesia, S.P., Raya, J., No, B., Km, R.W., Regency, B., Java, W., 2023. Analisis Hubungan Efektivitas Obat Antiviral Terhadap Lama Rawat Pasien Covid-19 Rawat Inap di Rumah Sakit Ananda Babelan Tahun 2021. Jurnal Ilmu Kefarmasian.
Haqim, L.N., Setiadi, A.A.P., 2023. Perbandingan Efektivitas dan Efek Samping Antivirus Favipiravir dan Remdesivir Pada Pasien COVID-19. Malahayati Nursing Journal 5, 1868–1875. https://doi.org/10.33024/mnj.v5i6.8743
Damayanti, H., Sajinadiyasa, I. G. K., Risni, H. W., & Sauriasari, R. (2021). The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali, Indonesia. Kesmas: National Public Health Journal, 16(4). https://doi.org/10.21109/kesmas.v16i4.5433
DOI: https://doi.org/10.15416/pcpr.v8i3.50046
Refbacks
- There are currently no refbacks.
